- Home
- IVA vs EDIT Comparison
IVA vs EDIT Comparison
Compare IVA & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- EDIT
- Stock Information
- Founded
- IVA 2011
- EDIT 2013
- Country
- IVA France
- EDIT United States
- Employees
- IVA N/A
- EDIT N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVA Health Care
- EDIT Health Care
- Exchange
- IVA Nasdaq
- EDIT Nasdaq
- Market Cap
- IVA 127.0M
- EDIT 108.1M
- IPO Year
- IVA 2020
- EDIT 2016
- Fundamental
- Price
- IVA $2.84
- EDIT $1.92
- Analyst Decision
- IVA Strong Buy
- EDIT Buy
- Analyst Count
- IVA 4
- EDIT 14
- Target Price
- IVA $13.25
- EDIT $8.08
- AVG Volume (30 Days)
- IVA 10.9K
- EDIT 5.8M
- Earning Date
- IVA 03-26-2025
- EDIT 03-03-2025
- Dividend Yield
- IVA N/A
- EDIT N/A
- EPS Growth
- IVA N/A
- EDIT N/A
- EPS
- IVA N/A
- EDIT N/A
- Revenue
- IVA $20,652,523.00
- EDIT $61,759,000.00
- Revenue This Year
- IVA N/A
- EDIT N/A
- Revenue Next Year
- IVA $197.46
- EDIT N/A
- P/E Ratio
- IVA N/A
- EDIT N/A
- Revenue Growth
- IVA N/A
- EDIT 150.95
- 52 Week Low
- IVA $1.53
- EDIT $1.12
- 52 Week High
- IVA $4.50
- EDIT $11.58
- Technical
- Relative Strength Index (RSI)
- IVA 69.74
- EDIT 55.72
- Support Level
- IVA $2.58
- EDIT $1.12
- Resistance Level
- IVA $2.80
- EDIT $3.30
- Average True Range (ATR)
- IVA 0.15
- EDIT 0.30
- MACD
- IVA 0.04
- EDIT 0.12
- Stochastic Oscillator
- IVA 81.31
- EDIT 36.70
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.